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Reproductive factors are associated with reduced risk of breast cancer, but less is known about whether there is differential
protection against subtypes of breast cancer. Assuming reproductive factors act through hormonal mechanisms they should protect
predominantly against cancers expressing oestrogen (ER) and progesterone (PR) receptors. We examined the effect of reproductive
factors on subgroups of tumours defined by hormone receptor status as well as histology using data from the NIHCD Women’s
Contraceptive and Reproductive Experiences (CARE) Study, a multicenter case–control study of breast cancer. We estimated odds
ratios (ORs) and 95% confidence intervals (CIs) as measures of relative risk using multivariate unconditional logistic regression
methods. Multiparity and early age at first birth were associated with reduced relative risk of ERþPRþtumours (P for
trend¼0.0001 and 0.01, respectively), but not of ER PR  tumours (P for trend¼0.27 and 0.85), whereas duration of breastfeeding
was associated with lower relative risk of both receptor-positive (P for trend¼0.0002) and receptor-negative tumours (P¼0.0004).
Our results were consistent across subgroups of women based on age and ethnicity. We found few significant differences by
histologic subtype, although the strongest protective effect of multiparity was seen for mixed ductolobular tumours. Our results
indicate that parity and age at first birth are associated with reduced risk of receptor-positive tumours only, while lactation is
associated with reduced risk of both receptor-positive and -negative tumours. This suggests that parity and lactation act through
different mechanisms. This study also suggests that reproductive factors have similar protective effects on breast tumours of lobular
and ductal origin.
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The epidemiologic evidence that reproductive factors such as
number of full-term pregnancies, age at first full-term pregnancy
a n dd u r a t i o no fb r e a s t f e e d i n ga r es t r o n g l yp r e d i c t i v eo fb r e a s t
cancer risk is substantial (Kelsey et al, 1993; Collaborative Group on
Hormonal Factors in Breast Cancer, 2002). We recently confirmed
these findings in the Women’s Contraceptive and Reproductive
Experiences (CARE) Study and showed that these effects are similar
in African-American and White women (Ursin et al,2 0 0 4 ) .
Both multiparity and age at first pregnancy may exert their
protective effects on breast cancer through hormonal mechanisms
(Bernstein et al, 1985; Garcia-Closas et al, 2002), either through
direct action on sex steroids or through hormone-induced breast
cell differentiation (Russo et al, 1992). The protective effects of
lactation may occur because of both hormonal (Petrakis et al,
1987; Russo and Russo, 1994) and nonhormonal mechanisms
(Murrell, 1991). It has previously been proposed that hormonal
breast cancer risk factors ought to be predominantly associated
with tumours that express oestrogen (ER) and progesterone (PR)
receptors, and less so with receptor-negative tumours (McTiernan
et al, 1986; Stanford et al, 1987; Potter et al, 1995; Enger et al, 2000;
Ursin et al, 2002). However, the studies that have addressed the
effect of reproductive factors on breast tumours of different
receptor status have yielded mixed results (Hildreth et al, 1983;
McTiernan et al, 1986; Stanford et al, 1987; Cooper et al, 1989;
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sPotter et al, 1995; Yoo et al, 1997; Huang et al, 2000; Britton et al,
2002; Cotterchio et al, 2003).
The histology of the tumour may complicate this picture even
further. It has been hypothesised that lobular cancers may be more
strongly associated with certain hormonal risk factors such as
postmenopausal hormone therapy use (Li et al, 2000; Daling et al,
2002). However, this has not been found in all studies (Ursin et al,
2002), and there is some evidence that early age at menarche, late
age at menopause and obesity are more strongly associated with
ductal tumours than lobular tumours (Li et al, 2003).
Tumour histology may also be related to receptor status.
Lobular tumours are more often receptor positive than ductal
tumours (Chu and Anderson, 2002), and it would therefore seem
obvious that overall, lobular tumours should be associated with
hormonal factors, but once receptor status has been taken into
account, it is not clear whether any of the histological subtypes
should be more or less associated with hormonal factors.
We combine epidemiological data with data from pathology
reports of cases who participated in the Women’s CARE Study to
examine the relationships of reproductive factors with different
types of breast tumours to gain insight into mechanisms that may
be operating. If parity and breastfeeding act through hormonal
mechanisms, we expect that they will protect predominantly
against tumours that express ER and PR (ERþPRþ tumours),
while if they act through a nonhormonal mechanism, they will be
associated with hormone receptor-positive and -negative tumours
to an equal extent.
We also evaluate the associations between reproductive factors
and development of tumours of different histologies in all women
combined as well as by ERPR status.
MATERIAL AND METHODS
The Women’s CARE Study is a population-based case–control
study of breast cancer designed to address the role of reproductive,
contraceptive and lifestyle factors on the breast cancer risk of
White and African-American women ages 35–64 years in five US
regions (Atlanta, Seattle, Detroit, Philadelphia and Los Angeles).
The design and methods of this study have previously been
described in detail (Marchbanks et al, 2002).
Cases
Case patients were diagnosed with pathologically confirmed
invasive breast cancer between July 1994 and April 1998, and
were identified by the Surveillance, Epidemiology and End Results
(SEER) cancer registries in Atlanta, Seattle, Detroit and Los
Angeles, or from hospitals in Philadelphia. We restricted eligibility
to US-born English-speaking women. We oversampled younger
case patients and African-American case patients to maximise
their numbers in the study, and we randomly sampled older White
case patients to achieve approximately equal numbers of case
patients in each 5-year age group. Of the 5982 eligible case
patients, we interviewed 4575 (76.5%), including 2953 White
patients and 1622 African-Americans.
Controls
Control subjects were randomly selected from a pool of eligible
women identified through random digit dialling (RDD) identified
between July 1994 and June 1998. They were US-born English-
speaking women who had never been diagnosed with invasive or
in situ breast cancer. Control subjects were frequency matched to
case patients by study centre, race and 5-year age group. We
successfully screened 82% of residential households called. Of the
5956 eligible women selected as control subjects, we interviewed
4682 (78.6%), including 3021 White subjects and 1661 African
Americans.
Data collection
Risk factor information was obtained from an in-person interview
using a structured questionnaire that included questions on
demographics, reproductive history (including breastfeeding),
medical history including use of exogenous hormones, family
history of cancer and other lifestyle factors. Information was
recorded up to the date of diagnosis (month and year) for case
patients or the date of initial household contact by RDD for control
subjects. All cases and controls were interviewed between
September 1994 and December 1998. Informed consent was
obtained from all participants. Study protocols were approved by
the Institutional Review Board at each participating centre.
Receptor status
Oestrogen receptor and PR status of case patients was recorded
from the pathology record when available at each study centre. All
SEER registries routinely collect this information for breast cancer,
specifically they collect the laboratory results recorded in the
medical records at the time of diagnosis. Overall, 3969 (86.8%) of
case patients had ER status data available. Among those missing
ER status, the pathology record indicated that the test had not been
carried out for 153 cases, it had been ordered but was not available
for 171 cases and the information was missing for 252 cases. An
additional 30 cases had ER status listed as borderline and were
also excluded from these analyses. We had PR information on 3795
women (83.0%). An additional 179 were ordered but results were
not available, 238 were not carried out and no information was
available on 319. The PR status of 44 was borderline and these were
excluded from the analyses. Both ER and PR status were available
on 3771 cases, or 82.4%. The percentage of participants with both
ER and PR status available by site were: Atlanta 91.5%, Detroit
70.3%, Los Angeles 79.0%, Philadelphia 72.3% and Seattle 93.5%.
Histology
We conducted separate analyses by histology for 3455 ductal
tumours (International Classification of Diseases for Oncology,
ICD-O morphology code 8500), 274 lobular tumours (ICD-O
morphology code 8520) and 261 mixed ductolobular tumours
(ICD-O morphology code 8522). An additional 577 tumours of
other histologies were not included in these analyses.
Analyses
We evaluated the following reproductive variables: gravidity (ever
pregnant vs never pregnant), parity (no full-term pregnancy vs
full-term pregnancy, defined as longer than 6 months (426
weeks)), number of pregnancies, number of full-term pregnancies,
age at first full-term pregnancy, years since last full-term
pregnancy and duration of breastfeeding.
We excluded 21 women (seven cases and 14 controls) from the
analyses because of unknown information on one or more
pregnancy or breastfeeding variable These exclusions left us with
4668 controls and 3764 cases for the ERPR analyses. For the
histology analyses, we excluded one additional case with missing
parity and ERPR information. Thus, we ended up with 3990 cases
for the histology analyses. A total of 11 women who had unknown
ages at menarche were assigned the median age of 12 years and
retained in all analyses.
For each stratum of ERPR status, we estimated odds ratios (ORs)
and 95% confidence intervals (CIs) as measures of relative risk
using unconditional logistic regression methods (Breslow and Day,
1980), while controlling for a number of potentially confounding
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svariables that we had selected a priori. The following variables
were included in all models: age (35–39, 40–44, 45–49, 50–54,
55–59, 60–64 years), race (White and African-American), family
history of breast cancer (no first-degree family history, first-degree
(mother, sister or daughter) family history, unknown or adopted),
age at menarche (p11, 12, 13, 413 years), study centre (five sites)
and education (phigh school, technical school or some college,
college graduate). Where appropriate, we also adjusted for age at
first full-term pregnancy (p19, 20–24, 25–29, X30 years) and
number of full-term pregnancies (1, 2, 3, 4, X5). For analyses of all
women combined, we used never pregnant women as the reference
group. For the analyses of age at first birth and total breastfeeding,
we only included parous women. The reference group for total
breastfeeding was parous women who had never breastfed. All
adjustment variables were included as categorical variables in the
models. We report the P-values from trend tests (Wald statistics)
from the case–control analyses in the tables. All P-values reported
are two-sided.
To determine whether the reproductive factors were associated
equally with breast cancer of different receptor statuses, we
excluded the controls, and defined ERþPRþ cases as ‘cases’ and
ER PR  cases as ‘controls’. We determined the ORs of being a
receptor-positive case associated with the various reproductive
factors, and estimated the tests for association or trend. A
statistically significant test of association or trend (likelihood
ratio test) from the case–case analysis suggested that the effect of
the exposure factor differed by receptor status. A similar
procedure was used for comparing ERþPR  cases and ER PRþ
cases with ER PR  cases, as well as for histology status, where we
evaluated whether either lobular or ductolobular cancers differed
from ductal tumours.
All analyses were performed using EPILOG (Epicenter Software,
Pasadena, CA, USA) or the SAS statistical package (SAS Institute,
Cary, NC, USA).
Study protocols were approved by the Institutional Review
Boards at each participating centre.
RESULTS
Cases with data on ER and PR had fewer children (w
2 P¼0.01),
somewhat later age at first birth (P¼0.0001), and breastfed longer
(P¼0.03) than those without data on ER and PR (Table 1). Table 2
shows the relative risk estimates of breast cancer associated with
reproductive factors by hormone receptor status. In general,
results for ERþPR  and ER PRþ tumours showed similar
associations to ERþPRþ tumours on all of the risk factors shown
in the table (P-values for all tests comparing ERþPRþ,
ERþPR  and ER PRþ receptor statuses 40.10, results not
shown), we focus our presentation on the differences between the
ERþPRþ and the ER PR  cancers. Ever having had a full-term
pregnancy was associated with a reduced OR for ERþPRþ
Table 1 Distribution of reproductive factors among all 4567 breast cancer cases and among the 3764 cases with known tumour oestrogen receptor (ER)
and progesterone receptor (PR) status and the 803 cases without known receptor status in the Women’s Contraceptive and Reproductive Experiences
(CARE) Study
All cases Cases with known ERPR status Cases without known ERPR status
N % N % N % v
2 P-value
a
Never pregnant 588 12.9 502 13.3 86 10.7
Pregnant but no full-term pregnancy 299 6.6 249 6.6 50 6.2
Ever full-term pregnancy 3680 80.6 3013 80.1 667 83.1 0.11
Never pregnant 588 12.9 502 13.3 86 10.7
1 770 16.9 633 16.8 137 17.1
2 1371 30.0 1153 30.6 218 27.2
3 841 18.4 680 18.1 161 20.1
4 381 8.3 297 7.9 84 10.5
5+ 317 6.9 250 6.6 67 8.3 0.01
Pregnant but no full-term pregnancy 299 6.6 249 6.6 50 6.2
Parous women
Age at first full-term pregnancy
p19 1044 28.4 806 26.8 238 35.7
20–24 1367 37.2 1126 37.4 241 36.1
25–29 777 21.1 667 22.1 110 16.5 0.0001
30+ 492 13.4 414 13.7 78 11.7
Ever breastfeeding
No 1653 44.9 1333 44.2 320 48.0
Yes 2027 55.1 1680 55.8 347 52.0 0.08
Ever breastfeeding at least 2 weeks
Never breastfeeding 1653 44.9 1333 44.2 320 48.0
Ever breastfeeding o2 weeks 151 4.1 123 4.1 28 4.2
Ever breastfeeding 2+ weeks 1876 51.0 1557 51.7 319 47.8 0.19
Total breastfeeding (months)
0 1653 44.9 1333 44.2 320 48.0
o1 277 7.5 219 7.3 58 8.7
1–6 820 22.3 699 23.2 121 18.1
7–23 663 18.0 550 18.3 113 16.9
24+ 267 7.3 212 7.0 55 8.3 0.03
aw
2 P-value for the difference between the cases with known and the cases without known ERPR status.
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sTable 2 Odds ratios (OR)
a and 95% confidence intervals (CI) of breast cancer of different receptor status associated with reproductive factors
ER+PR+ (N¼2130) ER PR  (N¼1081) ER+PR  (N¼368) ER PR+ (N¼185)
All women Case Control OR 95% CI Case Control OR 95% CI Case Control OR 95% CI Case Control OR 95% CI
Ever pregnancy
No 315 481 1.00 109 481 1.00 52 481 1.00 26 481 1.00
Yes 1815 4187 0.70 0.60–0.82 972 4187 1.02 0.82–1.28 316 4187 0.71 0.52–0.98 159 4187 0.75 0.48–1.15
P-value for comparison to
ER PR  tumours
b
0.0019 0.085 0.21
Ever full-term pregnancy
Never pregnant 315 481 1.00 109 481 1.00 52 481 1.00 26 481 1.00
Only non-full-term 158 322 0.77 0.61–0.99 58 322 0.75 0.52–1.06 26 322 0.86 0.52–1.42 7 322 0.36 0.16–0.85
Ever full-term 1657 3865 0.69 0.59–0.81 914 3865 1.05 0.84–1.32 290 3865 0.70 0.51–0.96 152 3865 0.79 0.51–1.23
P-value for comparison to
ER PR  tumours
0.0005 0.051 0.27
Number of full-term pregnancies
Never pregnant 315 481 1.00 109 481 1.00 52 481 1.00 26 481 1.00
1 345 717 0.78 0.64–0.95 183 717 1.07 0.82–1.40 60 717 0.85 0.57–1.27 45 717 1.15 0.69–1.90
2 650 1355 0.74 0.63–0.89 350 1355 1.13 0.89–1.45 102 1355 0.71 0.50–1.02 51 1355 0.72 0.44–1.18
3 380 905 0.65 0.53–0.78 200 905 0.99 0.76–1.30 68 905 0.66 0.45–0.98 32 905 0.72 0.42–1.24
4 159 443 0.55 0.43–0.70 89 443 0.90 0.65–1.24 37 443 0.71 0.45–1.12 12 443 0.56 0.28–1.15
5+ 123 445 0.42 0.33–0.55 92 445 0.94 0.68–1.31 23 445 0.39 0.23–0.67 12 445 0.56 0.27–1.18
Trend P
c 0.0001 0.27 0.0009 0.009
P-value for comparison to
ER PR  tumours
0.00006 0.015 0.04
ER+PR+ (N¼1657) ER PR  (N¼914) ER+PR  (N¼290) ER PR+ (N¼152)
Parous only
d Case Control OR 95% CI Case Control OR 95% CI Case Control OR 95% CI Case Control OR 95% CI
Age at first full-term pregnancy
p19 391 1190 1.00 303 1190 1.00 67 1190 1.00 45 1190 1.00
20–24 639 1460 1.16 0.99–1.36 314 1460 0.92 0.76–1.10 127 1460 1.32 0.95–1.83 46 1460 0.85 0.54–1.32
25–29 392 718 1.44 1.19–1.75 184 718 1.06 0.84–1.34 58 718 1.23 0.81–1.86 33 718 1.15 0.69–1.94
30+ 235 497 1.22 0.97–1.54 113 497 0.91 0.68–1.22 38 497 1.14 0.70–1.87 28 497 1.17 0.64–2.12
Trend P 0.01 0.85 0.59 0.45
P-value for comparison to
ER PR  tumours
0.07 0.66 0.29
Years since last full-term pregnancy
e
10+ 1121 2625 1.00 584 2625 1.00 198 2625 1.00 84 2625 1.00
7–9 85 184 1.21 0.88–1.66 53 184 0.95 0.66–1.38 12 184 1.47 0.72–3.00 5 184 0.55 0.20–1.50
3–6 78 200 1.03 0.73–1.46 54 200 0.86 0.58–1.28 12 200 1.55 0.72–3.34 7 200 0.73 0.28–1.85
o3 25 127 0.55 0.33–0.91 37 127 0.87 0.54–1.40 6 127 1.35 0.49–3.72 9 127 1.42 0.55–3.66
Trend P 0.15 0.46 0.32 0.75
P-value for comparison to
ER PR  tumours
0.64 0.17 0.60
Ever breastfeeding
No 717 1533 1.00 422 1533 1.00 130 1533 1.00 64 1533 1.00
Yes 940 2332 0.78 0.69–0.89 492 2332 0.78 0.66–0.91 160 2332 0.80 0.61–1.03 88 2332 0.92 0.64–1.32
P-value for comparison to
ER PR  tumours
0.84 0.61 0.45
Ever breastfeeding at least 2 weeks
Never breastfeeding 717 1533 1.00 422 1533 1.00 130 1533 1.00 64 1533 1.00
Only o2 weeks 65 150 0.94 0.69–1.29 40 150 0.94 0.65–1.37 9 150 0.74 0.36–1.49 9 150 1.33 0.64–2.76
Ever 2+ weeks 875 2182 0.77 0.68–0.88 452 2182 0.76 0.65–0.90 151 2182 0.80 0.61–1.05 79 2182 0.88 0.61–1.28
P-value for comparison to
ER PR  tumours
0.91 0.75 0.58
Total breastfeeding (month)
0 717 1533 1.00 422 1533 1.00 130 1533 1.00 64 1533 1.00
o1 123 306 0.85 0.67–1.08 62 306 0.76 0.56–1.02 18 306 0.69 0.41–1.15 16 306 1.27 0.72–2.25
1–6 376 902 0.78 0.67–0.91 219 902 0.88 0.73–1.07 66 902 0.80 0.58–1.11 38 902 0.98 0.63–1.50
7–23 323 775 0.79 0.67–0.94 149 775 0.68 0.54–0.85 53 775 0.81 0.57–1.16 25 775 0.74 0.44–1.23
24+ 118 349 0.69 0.54–0.89 62 349 0.65 0.48–0.89 23 349 0.89 0.54–1.47 9 349 0.67 0.31–1.44
Trend P 0.0002 0.0004 0.26 0.02
P-value for comparison to
ER PR 
0.71 0.93 0.99
aORs are adjusted for categorical variables of age, race, family history of breast cancer, age at menarche, education and study site (see text).
bP-value for a test for association or
trend (likelihood ratio test) from case–case analyses where ‘controls’ represent ER PR  cases (see text).
cP-value from a test for trend (Wald statistic) from case–control
analyses.
dORs for parous women are also adjusted for number of full-term pregnancies and age at first full-term pregnancy.
eAnalyses for years since last full-term pregnancy
restricted to women with 2+ full-term pregnancies.
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stumours (OR 0.69, 95% CI 0.59–0.81), while no such effect was
observed for ER PR  tumours (OR 1.05, 95% CI 0.84–1.32, P
comparing cases by ERPR status¼0.0005). Being multiparous was
associated with reduced ORs of ERþPRþ tumours, but not of
ER PR  tumours (P comparing cases by ERPR status¼0.00006),
with five or more full-term pregnancies conferring an estimated
58% reduction in risk of ERþPRþ tumours.
Among parous women, older ages at first birth were associated
with modest increases in relative risk estimates of ERþPRþ
tumours, but not ER PR  tumours, although the test comparing
receptor status did not achieve statistical significance (P¼0.07).
On the other hand, the effects of breastfeeding did not differ by
receptor status. Among parous women, the relative risk estimates
for both ERþPRþ and ER PR  tumours were statistically
significantly reduced among those who had breastfed compared to
those who had not. The effect of total duration of breastfeeding
was remarkably similar for both ERþPRþ and ER PR 
tumours. Compared to women who never breastfed, women who
breastfed 24 months or longer were at an estimated 31 and 35%
lower relative risk of ERþPRþ and ER PR  tumours,
respectively (P comparing cases by ERPR status¼0.71).
Table 3 shows the OR per full-term pregnancy as well as the OR
per 12 months of breastfeeding by receptor status in different
subgroups of women. The results were similar when we restricted
the analyses to White women or to African-American women, or
when analyses were restricted to specific race–age subgroups.
The only exception was in White women under age 50 where
multiparity was associated with a statistically significant relative
risk reduction for both receptor-positive and -negative tumours
(results not shown).
Histology
In Table 4, we show the effect of reproductive factors on tumours
of ductal, ductolobular and lobular histology. Ever having
had a full-term pregnancy was associated with an OR of
0.80 (95% CI 0.69–0.92) for ductal tumours, OR of 0.89 (95% CI
0.60–1.33) for lobular tumours and OR of 0.65 (95% CI 0.45–0.93)
for ductolobular cancers. Increasing number of full-term
pregnancies was associated with a strong protective effect for
ductal tumours (P for trend¼0.00001) and for ductolo-
bular tumours (P for trend¼0.001). There was no significant
protective trend for lobular tumours (P¼0.19), but having had
four or more pregnancies was associated with an OR of 0.56,
similar to the OR of 0.62 for ductal tumours and 0.43
for ductolobular tumours. The tests comparing tumours of
other histologies with ductal tumours were not statistically
significant (all P-values¼0.20 or higher).
Women with later age at first full-term pregnancy were at higher
relative risk of lobular tumours than women with a first full-term
pregnancy before age 20 (P for trend¼0.02); this was not observed
for ductal (P for trend¼0.32) or ductolobular tumours (P for
trend¼0.92). The test for comparing lobular and ductal cancer
cases did not reach statistical significance (P¼0.11).
Total duration of breastfeeding showed slightly stronger risk
reductions for ductal than for either ductolobular or lobular
cancers, and was statistically significant only for ductal tumours.
However, the number of women with long duration of breastfeed-
ing was small in the lobular and ductolobular groups, and the tests
comparing lobular or ductolobular to ductal tumours were not
statistically significant.
When we did further analyses of tumours of different histologies
across different age and ethnic groups, the results were consistent
with those reported above (results not shown). When analyses
were limited to White women above age 50 with ERþPRþ
tumours, the only subgroup defined by age, race and receptor
status for which there were sufficient number of subjects to analyse
histology, the difference between ductolobular and ductal tumours
reached marginal statistical significance (OR per FTP for ductal
tumours 0.92 (95% CI 0.86–0.99) and OR for ductolobular
tumours 0.78 (95% CI 0.65–0.93), P¼0.05). We observed no
statistically significant differences in the relative risks estimates for
12 months of breastfeeding between tumours of the different
histologic subtypes (results not shown).
Table 3 Adjusted odds ratios (OR)
a and 95% confidence intervals (CI) per full-term pregnancy (FTP) and 12 months breastfeeding by oestrogen and
progesterone receptor (ERPR) status
OR (95% CI)
a per FTP
P-value for comparison
with ER PR  cases
b
OR (95% CI)
a per 12
months breastfeeding
P-value for comparison
with ER PR  cases
b
All women
ER PR  0.98 (0.94–1.03) Comparison group 0.91 (0.84–0.99) Comparison group
ER+PR+ 0.88 (0.85–0.91) 0.00001 0.93 (0.88–1.00) 0.51
ER PR+ 0.89 (0.80–0.99) 0.09 0.82 (0.65–1.04) 0.39
ER+PR  0.88 (0.82–0.95) 0.009 1.01 (0.89–1.14) 0.43
White women
ER PR  0.97 (0.91–1.04) Comparison group 0.87 (0.77–0.97) Comparison group
ER+PR+ 0.87 (0.83–0.91) 0.004 0.92 (0.85–0.99) 0.33
African-American women
ER PR  0.99 (0.93–1.05) Comparison group 0.97 (0.85–1.11) Comparison group
ER+PR+ 0.88 (0.83–0.94) 0.002 0.98 (0.87–1.11) 0.89
All women age 50+
ER PR  1.03 (0.97–1.09) Comparison group 0.97 (0.85–1.10) Comparison group
ER+PR+ 0.89 (0.85–0.93) 0.0001 0.95 (0.86–1.04) 0.93
All women under age 50
ER PR  0.93 (0.86–0.99) Comparison group 0.88 (0.79–0.99) Comparison group
ER+PR+ 0.85 (0.80–0.91) 0.06 0.93 (0.86–1.02) 0.39
aORs are adjusted for categorical variables of age, race, family history of breast cancer, age at menarche, education and study site (see text). Women with non-full-term
pregnancies were not included in these analyses. Only parous women were included in the analyses of breastfeeding.
bP-value for a test for trend from a case–case analyses
where ‘cases’ represent ER+PR+ cases (see text).
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hormone therapy, the results were very similar, with no differences
between the relative risk estimates of the different histologic types
for either full-term pregnancy or breastfeeding.
DISCUSSION
Our recent evaluation of reproductive factors from the CARE study
(Ursin et al, 2004) found that the effects of reproductive factors
Table 4 Adjusted odds ratios (ORs)
a and 95% confidence intervals (CI) of breast cancer of different histology associated with reproductive factors
Ductal (N¼3455) Lobular (N¼274) Ductolobular (N¼261)
All women Case Control OR 95% CI Case Control OR 95% CI Case Control OR 95% CI
Ever pregnancy
No 441 481 1.00 31 481 1.00 41 481 1.00
Yes 3014 4187 0.79 0.69–0.91 243 4187 0.91 0.61–1.35 220 4188 0.66 0.46–0.94
P-value for comparison to ductal tumours
b 0.47 0.34
P-value for comparison to ductolobular tumours
c 0.28
Ever full-term pregnancy
Never pregnant 441 481 1.00 31 481 1.00 41 481 1.00
Only non-full-term pregnancy 220 322 0.74 0.60–0.92 20 322 1.09 0.60–1.96 20 322 0.75 0.43–1.31
Ever full-term pregnancy 2794 3865 0.80 0.69–0.92 223 3865 0.89 0.60–1.33 200 3866 0.65 0.45–0.93
P-value for comparison to ductal tumours 0.55 0.30
P-value for comparison to ductolobular tumours 0.30
Number of full-term pregnancies
Never pregnant 441 481 1.00 31 481 1.00 41 481 1.00
1 599 717 0.92 0.77–1.09 31 717 0.74 0.44–1.25 43 717 0.76 0.48–1.19
2 1039 1355 0.84 0.72–0.98 86 1355 1.01 0.65–1.55 79 1355 0.70 0.47–1.05
3 631 905 0.75 0.63–0.89 68 905 1.10 0.70–1.73 47 905 0.62 0.40–0.97
4+ 525 888 0.62 0.52–0.74 38 888 0.56 0.33–0.93 31 889 0.43 0.26–0.71
Trend P
d 0.00001 0.19 0.001
P-value for comparison to ductal tumours 0.35 0.24
P-value for comparison to ductolobular tumours 0.20
Ductal (N¼2794) Lobular (N¼223) Ductolobular (N¼200)
Parous only
e Case Control OR 95% CI Case Control OR 95% CI Case Control OR 95% CI
Age at first full-term pregnancy
p19 808 1190 1.00 42 1190 1.00 53 1190 1.00
20–24 1029 1460 1.01 0.88–1.14 96 1460 1.66 1.11–2.47 71 1461 0.90 0.61–1.33
25–29 576 718 1.13 0.96–1.33 59 718 2.31 1.44–3.68 48 718 1.18 0.75–1.87
30+ 381 497 1.05 0.86–1.27 26 497 1.61 0.89–2.91 28 497 0.90 0.51–1.58
Trend P 0.32 0.02 0.92
P-value for comparison to ductal tumours 0.11 0.68
P-value for comparison to ductolobular tumours 0.23
Ever breastfeeding
No 1262 1533 1.00 91 1533 1.00 82 1533 1.00
Yes 1532 2332 0.80 0.72–0.89 132 2332 0.90 0.67–1.21 118 2333 0.90 0.65–1.23
P-value for comparison to ductal tumours 0.41 0.64
P-value for comparison to ductolobular tumours 0.53
Ever breastfeeding at least 2 weeks
Never breastfeeding 1262 1533 1.00 91 1533 1.00 82 1533 1.00
Ever breastfeeding o2 weeks 115 150 0.94 0.72–1.21 11 150 1.34 0.64–2.41 9 150 1.17 0.57–2.42
Ever breastfeeding 2+ weeks 1417 2182 0.79 0.71–0.88 121 2182 0.87 0.64–1.18 109 2183 0.87 0.63–1.21
P-value for comparison to ductal tumours 0.44 0.88
P-value for comparison to ductolobular tumours 0.55
Total breastfeeding (months)
0 1262 1533 1.00 91 1533 1.00 82 1533 1.00
o1 207 306 0.84 0.69–1.02 21 306 1.34 0.69–1.88 16 306 0.97 0.56–1.71
1–6 608 902 0.80 0.70–0.91 48 902 0.84 0.58–1.22 52 902 0.98 0.67–1.42
7–23 522 775 0.81 0.70–0.94 45 775 0.88 0.59–1.31 31 776 0.68 0.43–1.08
24+ 195 349 0.72 0.59–0.89 18 349 0.83 0.47–1.47 19 349 1.07 0.60–1.91
Trend P 0.0001 0.34 0.43
P-value for comparison to ductal tumours 0.56 0.71
P-value for comparison to ductolobular tumours 0.85
aORs are adjusted for categorical variables of age, race, family history of breast cancer, age at menarche, education and study site (see text).
bP-value for a test for association or
trend (likelihood ratio test) from a case–case analyses where ‘cases’ represent cases with ductal tumours (see text).
cP-value for a test for association or trend (likelihood ratio
test) from a case–case analyses where ‘cases’ represent cases with ductolobular tumours.
dP-value from a test for trend (Wald statistic) from case–control analyses.
eORs for
parous women are also adjusted for number of full-term pregnancies and age at first full-term pregnancy.
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women. In particular, parity and lactation had similar protective
effects in the two racial groups.
In the present analyses, we found that multiparity and early
age at first birth were associated with reduced relative risk of
ERþPRþ tumours, but not of ER PR  tumours. The relative
risk reduction observed with duration of breastfeeding did not
differ between receptor-negative and -positive tumours. Our
results were consistent across subgroups of women based on their
age and ethnicity.
Previous studies of the effects of parity or age at first full-term
pregnancy (or age at first birth) on tumours of different receptor
statuses have been mixed. Two studies found similar effects of
parity on receptor-positive and -negative tumours (Yoo et al, 1997;
Britton et al, 2002). One study suggested a protective effect of
multiparity on ERþPRþ tumours, but not receptor-negative
tumours; however, tests comparing these tumour types were not
statistically significant, possibly because of few (n¼80) ER PR 
cases (Potter et al, 1995). Another study found similar effects of
parity on receptor-positive and -negative tumours among post-
menopausal women (Cotterchio et al, 2003), while among
premenopausal women, the inverse association with parity was
only observed for ERþPRþ cases. Only one of these previous
studies had a sample size greater than ours (Cotterchio et al, 2003),
but that study had a broader age range (25–74 years), and all
results were presented separately for pre- and postmenopausal
women. Thus, lack of statistical power in these previous studies
may explain why results from our study are only partially
consistent with them.
Several studies have addressed the effect of age at first birth on
receptor status of breast tumours (Potter et al, 1995; Yoo et al,
1997; Huang et al, 2000; Britton et al, 2002; Cotterchio et al, 2003).
Consistent with our findings, three of these studies found evidence
that late age at first birth was associated with receptor-positive
tumours only (Potter et al, 1995; Huang et al, 2000; Cotterchio
et al, 2003). Our results on breastfeeding are also consistent with
the few previous studies that have addressed this (Hildreth et al,
1983; McTiernan et al, 1986; Cooper et al, 1989; Yoo et al, 1997;
Huang et al, 2000; Britton et al, 2002; Cotterchio et al, 2003).
We had few women with ER PRþ and ERþPR  tumours,
but, in general, results for these tumours were similar to those
for ERþPRþ tumours. Previous reports have not drawn strong
conclusions on the associations between these subtypes and
reproductive factors (Huang et al, 2000; Britton et al, 2002). It is
possible that some of the similarity between ERþPRþ and
ER PRþ tumours is due to some ERþPRþ tumours that are
misclassified as ER PRþ (Horwitz, 1988). By using the combined
status of ER and PR, we reduce the problem of including any
tumours where one of the receptor statuses was mislabelled.
The finding of a protective effect of pregnancies only on
receptor-positive tumours support the evidence suggesting that
pregnancies protect against breast cancer primarily through
hormonal mechanisms. Pregnancies have been found to reduce
plasma levels of oestrogen (oestrone, oestradiol and oestriol)
(Bernstein et al, 1985; Garcia-Closas et al, 2002) and follicular
phase levels of progesterone (Garcia-Closas et al, 2002), increase
levels of sex hormone-binding globulin (Bernstein et al, 1985) and
modify the oestrogen changes that occur with age (Dorgan et al,
1995). Either as a consequence of these changes or of other
pregnancy changes, the resulting breast changes are characterised
by further differentiation of the terminal duct lobular units (Russo
et al, 1992).
Lactation has also been proposed to protect against breast
cancer through hormonal mechanisms by postponing the resump-
tion of ovulatory menstrual cycles after a pregnancy, by increasing
the differentiation of breast tissue (Russo and Russo, 1994) or by
altering oestrogen levels in the breast (Petrakis et al, 1987). In
addition, it has been proposed that lactation also has a direct
mechanical effect by which carcinogenic agents are excreted from
the breast ductal tissue (Murrell, 1991). Our findings suggest that
the effect of lactation may not be hormonal, or that at least the
mechanisms for this protection are different from those for
pregnancies. For instance, the effect of lactation could still be
through hormonal mechanisms if lactation exerts its effect at a
time period prior to when the hormonal receptor status of a future
tumour is developing.
We found few differences between lobular and ductal tumours.
Increasing parity had a greater impact on ductal and ductolobular
tumours than on lobular tumours, but age at first full-term
pregnancy was slightly more protective against lobular cancers.
Thus, overall reproductive factors seem to protect against all
three histological types. In general, the findings for ductolobular
tumours were more similar to ductal than to lobular tumours.
These findings are consistent with a recent gene expression
study (Zhao et al, 2004), which found that about half of the
lobular cancers had similar gene expression patterns to ductal
tumours, while the remaining ‘typical’ lobular cancers had a
different gene expression pattern. However, in these analyses we
found little evidence that these reproductive factors act differently
on either ductal or lobular tumours, with the possible excep-
tion that early age at first birth was most strongly associated
with lower risk of lobular cancers, and that ductolobular tumours
were associated with the strongest risk reduction per full-term
pregnancy.
Although some evidence exists that lobular tumours are more
strongly associated with hormonal risk factors such as postmeno-
pausal hormone use and oral contraceptive use (Li et al, 2000;
Daling et al, 2002) than ductal tumours, this has not been found in
all studies (Ursin et al, 2002). Further, one study found that early
age at menarche, late age at menopause and obesity are more
strongly associated with ductal tumours than lobular tumours (Li
et al, 2003). Our study suggests that ductolobular tumours should
either be treated as a separate entity or combined with ductal
cancers, but should not be combined with lobular cancers. Further,
given the confounding effect of receptor status, studies of histology
should also separate tumours by receptor status of tumour.
One limitation of our study is that we used ERPR status as it
was reported in the pathology report. Although we presume the
majority of cases were assessed by immunohistochemistry, we
have no data on the methods used by each laboratory. It is possible
that some laboratories used different methods, or that the cutoff
for a positive receptor status varied between laboratories. It is also
possible that the methods varied geographically, by site. We did
adjust all analyses for study site and believe it unlikely that this
caused any of the observed associations, and that the most likely
effect, if any, would have been to bias our relative risk estimates
towards the null value.
Another weakness is that ERPR status was not available for all
cases. The frequency of unknown receptor status in our study
(17.6%) is remarkably similar to that reported by a prior study
conducted within the SEER registries (Chu and Anderson, 2002).
In that study of 123732 tumours, 18% were unknown and 5% were
not carried out. The reason for the large number of unknowns is
unclear, as is the information on the true distribution of ERPR
status among those reported as unknown (Chu and Anderson,
2002). Even though the CARE cases with no ERPR status were
more likely to be multiparous, give birth early and have breastfed
shorter, we think it is unlikely that receptor information on these
cases would have altered the results in our study.
In conclusion, high parity and early age at first birth were
associated with a reduction in risk only for ERþPRþ tumours.
Breastfeeding was associated with a reduction in risk for both
ERþPRþ and ER PR  tumours. Combined with previous
research, this suggests that parity and age at first birth act through
different mechanisms than breastfeeding. All reproductive factors
showed similar associations with both ductal, ductolobular and
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slobular tumours, suggesting that these tumours have similar
aetiologies.
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